首页> 中文期刊> 《中国医药指南》 >缬沙坦联合阿托伐他汀治疗高血压病合并持续性房颤的临床疗效评价

缬沙坦联合阿托伐他汀治疗高血压病合并持续性房颤的临床疗效评价

         

摘要

Objective To evaluate the clinical effect of valsartan combined with atorvastatin in treatment of hypertensive with persistant atrial ifbrillation. Methods 122 cases of hypertensive with persistant atrial ifbrillation were randomly divided into observation group(n=61)and control group(n=61), all cases were given routine treatment, based on this cases in the observation group were treated by valsartan combined with atorvastatin, observed the blood pressure, cardioversion rate, left atrial diameter(LAD)and left ventricular mass index(LVMI)of cases in two groups after treatment. Results The level of blood pressure, recovery ratio, LAD and LVMI of cases in observation group was better than that in control group, there was signiifcant difference between two groups(P<0.05). Conclusion Taking valsartan combined with atorvastatin in the treatment of hypertensive with persistant atrial ifbrillation has good clinical effect, worthy of further clinical application.%目的:评价缬沙坦联合阿托伐他汀治疗高血压病合并持续性房颤的临床疗效。方法将122例高血压病合并持续性房颤患者随机分为观察组(n=61)和对照组(n=61),对照组患者给予常规降压、改善心律治疗,在此基础上观察组患者采用缬沙坦联合阿托伐他汀治疗,观察两组患者治疗后的血压情况以及转复率、左房内径(LAD)及左室质量指数(LVMI)。结果观察组患者治疗后的血压水平、转复率、LAD以及LVMI优于对照组患者,组间差异有统计学意义(P<0.05)。结论采用缬沙坦联合阿托伐他汀治疗高血压病合并持续性房颤临床疗效可靠,值得临床进一步推广使用。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号